Indian Drugmakers Push for Input Price Caps as West Asia Conflict Drives Cost Surge
- By Newsdesk
- New Delhi
- Mar 20, 2026
India’s pharmaceutical industry is urging the government to intervene with price caps on key raw materials, as escalating tensions in West Asia trigger a sharp spike in input costs and disrupt global supply chains.
Industry stakeholders say the ongoing geopolitical conflict has significantly inflated the cost of essential inputs ranging from active pharmaceutical ingredients (APIs) to solvents and petrochemical derivatives placing immense pressure on manufacturers, particularly small and mid-sized firms. With raw material prices surging and logistics becoming costlier, companies warn that existing pricing controls on medicines are no longer sustainable.
At the heart of the issue is India’s strict drug pricing framework, which allows only a marginal annual increase linked to the wholesale price index for medicines listed under the National List of Essential Medicines (NLEM). This year’s permitted hike of just 0.6% has been widely criticised by industry players as inadequate to offset the steep rise in production costs. (The Economic Times reported)
Pharmaceutical companies argue that the mismatch between controlled drug prices and rapidly rising input costs is squeezing margins and threatening the viability of manufacturing essential medicines. Many firms are now preparing to formally approach authorities, seeking either a relaxation of price controls or the introduction of temporary caps on raw material prices to stabilise the sector.
The cost escalation has been exacerbated by disruptions in global trade routes and energy markets. The West Asia conflict has driven up crude oil prices and freight charges, both of which directly impact pharma manufacturing, as a large portion of drug inputs are derived from petrochemicals. Shipping delays and container shortages have further compounded the problem, extending transit times and inflating logistics expenses.
India’s heavy reliance on imports especially from China for APIs has made the sector particularly vulnerable. Any disruption in supply chains has a cascading effect on domestic production, raising the risk of higher drug prices and potential shortages if the situation persists.
Industry bodies have also highlighted that certain critical materials have witnessed steep price increases in recent months, in some cases rising by over 50%. This has forced manufacturers to absorb costs in the short term, but executives warn that such pressures are unsustainable without policy support.
While there are no immediate signs of widespread shortages, experts caution that prolonged geopolitical instability could strain inventories and disrupt the availability of essential medicines, including antibiotics and chronic disease treatments.
In response, drugmakers are calling for urgent government action, including the formation of a crisis task force and policy measures to cushion the impact of global volatility. Without timely intervention, the industry fears that cost pressures could eventually be passed on to consumers, undermining affordability and access to critical healthcare.
As the situation unfolds, the pharmaceutical sector often dubbed the “pharmacy of the world” finds itself at a critical juncture, balancing cost pressures with its mandate to ensure uninterrupted supply of affordable medicines.